AIMS: Alpha-fetoprotein (AFP) loses its potentials in treatment evaluation and prognosis
prediction in patients with AFP negative (≤ 20 ng/ml) hepatocellular carcinoma (HCC). The …

Alpha-fetoprotein (AFP) represents the most important biomarker for hepatocellular
carcinoma (HCC). The aim of this study was to identify the optimal staging system to predict …

Background Assessing the outcomes of surgeries for hepatocellular carcinoma (HCC)
patients who exceed the Milan criteria is necessary. Some studies have demonstrated that …

Background The value of alpha-fetoprotein (AFP) as a prognostic indicator in patients with
hepatocellular carcinoma (HCC) has been proposed in recent studies, but the evidence so …

Background The clinical value of alpha-fetoprotein (AFP) in patients with AFP-negative (< 20
ng/ml) hepatocellular carcinoma (HCC) who underwent curative resection remained …

Background Serum alpha-fetoprotein (AFP) is frequently used to predict posthepatectomy
outcomes in patients with hepatocellular carcinoma (HCC), but its predictive value is still not …

Background Preoperative α-fetoprotein (AFP) level levels may help select patients with
hepatocellular carcinoma (HCC) for surgery. The objective of the current study was to …

AIM: To identify the clinical outcomes of hepatocellular carcinoma (HCC) patients with
inconsistent α-fetoprotein (AFP) levels which were initially high and then low at recurrence …

Background There is currently no established model for predicting the recurrence of
hepatocellular carcinoma (HCC) in patients with negative alpha‐fetoprotein (AFP) after …

UICC staging) and tumor size. Although this study is retrospective, it is of interest both by the
issue raised which is still contradictory and by the large size of the cohort studied by the …